Provided by Tiger Trade Technology Pte. Ltd.

BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON

0.6799
+0.02383.63%
Volume:564.00
Turnover:375.88
Market Cap:27.76M
PE:-0.41
High:0.6799
Open:0.6799
Low:0.6799
Close:0.6561
52wk High:2.92
52wk Low:0.5600
Shares:40.83M
Float Shares:35.68M
Volume Ratio:0.23
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6400
EPS(LYR):-1.6400
ROE:-65.02%
ROA:-30.89%
PB:0.37
PE(LYR):-0.41

Loading ...

Company Profile

Company Name:
BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
105
Office Location:
Zeus Building,Unit 6-10,Rutherford Avenue,Harwell,Didcot,Oxfordshire,United Kingdom
Zip Code:
OX11 0DF
Fax:
- -
Introduction:
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Directors

Name
Position
Robin Wright
Chairman of the Board and Director
William Enright
Chief Executive Officer and Director
Alex Hammacher
Non-Executive Director
Anne M. Phillips
Non-Executive Director
Joseph C. F. Scheeren
Non-Executive Director
Karen T. Dawes
Non-Executive Director
Pierre A. Morgon
Non-Executive Director

Shareholders

Name
Position
William Enright
Chief Executive Officer and Director
Gemma Jones
Chief Financial Officer
Leon Hooftman
Chief Medical Officer